Leqvio (Inclisiran) Injection

Leqvio (inclisiran) is a prescription medication used to lower low-density lipoprotein cholesterol (LDL-C) levels in adults with hyperlipidemia or those at risk of cardiovascular disease. Developed by Novartis, Leqvio is an innovative treatment that targets a specific process in the liver to reduce cholesterol levels.

How It Works

Leqvio is a type of medication known as a small interfering RNA (siRNA) that works by interfering with the production of a protein called PCSK9 (proprotein convertase subtilisin/kexin type 9). PCSK9 is involved in the regulation of LDL receptors on the surface of liver cells. These receptors are responsible for removing LDL cholesterol from the blood. By inhibiting PCSK9 production, Leqvio helps increase the number of LDL receptors available to clear LDL cholesterol, leading to lower levels of LDL-C in the bloodstream.

Mechanism of Action:

1. Inhibition of PCSK9 Production: Inclisiran targets and degrades the messenger RNA (mRNA) that codes for PCSK9, reducing its levels in the liver.
2. Increased LDL Receptor Activity: With less PCSK9, more LDL receptors are available on liver cells, enhancing the uptake and clearance of LDL cholesterol from the blood.
3. Reduced LDL Cholesterol Levels: The overall effect is a significant reduction in LDL cholesterol levels, which can help reduce the risk of cardiovascular events.

Side Effects

While Leqvio is generally well-tolerated, it may cause side effects in some individuals.

Common Side Effects:

• Injection Site Reactions: Pain, redness, or swelling at the injection site.
• Muscle Pain: Mild to moderate muscle aches or discomfort.
• Headache: Occasional headaches reported by some patients.

Serious Side Effects:

• Allergic Reactions: Severe allergic reactions such as rash, itching, swelling, or difficulty breathing.
• Liver Issues: Rare cases of liver enzyme abnormalities may occur, requiring monitoring.
• Severe Muscle Pain: Myalgia or severe muscle pain may need evaluation.

Indications

Leqvio is indicated for specific conditions related to high cholesterol and cardiovascular risk.

Approved Indications:

1. Hyperlipidemia: To lower LDL cholesterol in adults with primary hyperlipidemia or mixed dyslipidemia.
2. Cardiovascular Risk Reduction: For individuals with atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond what is achieved with statins or other lipid-lowering therapies.

Contraindications

Certain conditions may contraindicate the use of Leqvio due to potential risks or interactions.

Contraindications:

1. Hypersensitivity to Inclisiran: Individuals with a known allergy to inclisiran or any component of the injection.
2. Severe Liver Impairment: Caution or avoidance is advised in patients with severe hepatic impairment due to potential effects on liver function.
3. Pregnancy and Breastfeeding: Not recommended for use during pregnancy or breastfeeding due to insufficient safety data.

Price in Different Countries

The cost of Leqvio (Inclisiran) Injection varies by country and is subject to local regulations and pricing structures. Below is a table showing approximate prices in different countries, with references for further information.

Country	Price (Per Injection)	Reference
United States	$3,000 – $3,500	GoodRx
United Kingdom	£2,500 – £3,000	NHS
Australia	AUD $4,000 – $4,500	PBS Australia
India	INR ₹70,000 – ₹85,000	1MG
Canada	CAD $3,500 – $4,000	Canada Pharmacy

Top 5 Global Brands

Leqvio is a unique product developed by Novartis, but several other companies produce related or competitive treatments for cholesterol management and cardiovascular risk reduction.

1. Novartis

• The original manufacturer of Leqvio, known for its innovation in lipid-lowering therapies.

2. Amgen

• Manufacturer of Repatha (evolocumab), another PCSK9 inhibitor used to lower LDL cholesterol.

3. Regeneron Pharmaceuticals

• Known for Praluent (alirocumab), a competitor to Leqvio in the PCSK9 inhibitor class.

4. Sanofi

• Co-developer with Regeneron for Praluent, offering an alternative to inclisiran.

5. Pfizer

• Develops various lipid-lowering medications and therapies for cardiovascular health.